The APPROACH Extension Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx)
ISIS 304801-CS7, The APPROACH Open Label Extension Study Volanesorsen (ISIS 304801) An Open-Label Extension Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
This study is a multi-center, open-label extension study for ISIS 304801-CS6. All patients will receive volanesorsen 300 mg once per week for 52 weeks. Following the Week 52 visit, patients will enter a 13 week post-treatment evaluation period.
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.